JDD Corner

Psoriasis Special Focus – JDD August Highlights and Editor Picks

Have you received your August issue of the JDD yet?  This month’s issue contains a special focus on Psoriasis, as August is Psoriasis Awareness Month!  Below are the issue highlights and Editor Picks for the August issue of JDD!

In Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years, high levels of efficacy were maintained through two years of continuous treatment.

Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasisgives an overview of psoriasis pathophysiology and how apremilast works to produce beneficial clinical effects in psoriasis.

In A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy,Bagel and colleagues show that treat-to-target was attainable in a real-world setting in a majority of patients as early as week 4.

In Cosmetic Versus Medicine: How Does Your Country Define Sunscreen?,authors describe how most countries classify sunscreens as a cosmetic, affecting the consumer’s perception of the purpose of sunscreen and underestimating its importance in public health.

A feasible and efficient method of preparing PLLA injectable product is proposed in A Novel, Optimized Method to Accelerate the Preparation of Injectable Poly-L-Lactic Acid by Sonication.

In UV Protection by Natural Products: C. myrrha Oil Versus Sunscreen, authors suggest development of natural sunscreen may aid in efforts to improve sunscreen use.

In Evaluation of the Performance of a Nature-Based Sensitive Skin Regimen in Subjects With Clinically Diagnosed Sensitive Skin, research suggests that nature-based whole formulas can be safely considered as an alternative to synthetic formulas.

Rapid Onset of Action in Patients with Moderate-to-Severe Plaque Psoriasis with Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination shows rapid onset of action, with apparent benefits over the individual active ingredients within 2 weeks.

Targeted advertisements that better demonstrate these concerns may help prompt under-treated patients to seek care with dermatologists in Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements.

Patients with mild to severe psoriasis were satisfied with Cal/BD foam after 15 days of use in Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.

In A Phase 2, Controlled, Dose-ranging Study of SB208, an Investigational Topical Nitric Oxide-releasing Drug, for the Treatment of Tinea pedis, results suggest the nitric oxide-releasing topical treatment was effective in clearing the dermatophytes that cause tinea pedis.

Did you enjoy this post?  View past issue highlights and more from JDD here!